Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

1.545 +0.005 (+0.32%)
Streaming Delayed Price Updated: 10:03 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,142
Open 1.590
Bid (Size) 1.500 (2)
Ask (Size) 1.630 (15)
Prev. Close 1.540
Today's Range 1.460 - 1.620
52wk Range 0.5100 - 2.860
Shares Outstanding 55,041,247
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
From Connect Biopharma Holdings Limited
Via GlobeNewswire

Performance

YTD
+27.7%
+27.7%
1 Month
+17.3%
+17.3%
3 Month
-11.7%
-11.7%
6 Month
+90.7%
+90.7%
1 Year
+22.6%
+22.6%

More News

Read More
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Posts Q2 Revenue Drop
Via The Motley Fool
Topics Intellectual Property
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - Ordinary Shares publicly traded?
Yes, Connect Biopharma Holdings Limited - Ordinary Shares is publicly traded.
What exchange does Connect Biopharma Holdings Limited - Ordinary Shares trade on?
Connect Biopharma Holdings Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares?
The ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares is CNTB on the Nasdaq Stock Market
What is the current price of Connect Biopharma Holdings Limited - Ordinary Shares?
The current price of Connect Biopharma Holdings Limited - Ordinary Shares is 1.545
When was Connect Biopharma Holdings Limited - Ordinary Shares last traded?
The last trade of Connect Biopharma Holdings Limited - Ordinary Shares was at 10/29/25 10:03 AM ET
What is the market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares?
The market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares is 85.04M
How many shares of Connect Biopharma Holdings Limited - Ordinary Shares are outstanding?
Connect Biopharma Holdings Limited - Ordinary Shares has 85M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.